Processa Pharmaceuticals Inc (PCSA) 시세

One year later joy strikes when it only hits .79 + 31% lol

PCSA.....................https://stockcharts.com/h-sc/ui?s=PCSA&p=W&b=5&g=0&id=p86431144783

BB PAVM > LCUD MHO

PCSA............................https://stockcharts.com/h-sc/ui?s=PCSA&p=W&b=5&g=0&id=p86431144783

PCSA............................https://stockcharts.com/h-sc/ui?s=PCSA&p=W&b=5&g=0&id=p86431144783

PCSA BLOWING UP

PCSA............................https://stockcharts.com/h-sc/ui?s=PCSA&p=W&b=5&g=0&id=p86431144783

PCSA BIO BEAST COMING IN

PCSA..........................https://stockcharts.com/h-sc/ui?s=PCSA&p=W&b=5&g=0&id=p86431144783

PCSA...$1.74...on strong news...🥳

PCSA new 52= week low

PCSA new 52=week low

PCSA.................................https://stockcharts.com/h-sc/ui?s=PCSAp=W&b=5&g=0&id=p86431144783

Processa Pharmaceuticals Announces FDA Clearance of IND Application for a Phase 2 Clinical Trial of NGC-Cap in Breast Cancer

News is excellent but with a $50 million shelf and the way they alienated retail with the reverse split and immediate offering they are getting a very limited response to what should be gangbuster news

HANOVER, MD., June 11, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, today announced positive efficacy results from the preliminary evaluation of its recently completed Phase 1b clinical trial which defined the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose Range (RP2DR) for Next Generation Capecitabine (NGC-Cap) administered to patients with Stage III or IV gastrointestinal tract (GI) cancer.

“We are encouraged by the preliminary efficacy analysis from our NGC-Cap Phase 1b dose-escalating safety/tolerability trial demonstrating some anti-tumor activity in patients with advanced GI cancer who have progressive cancer after relapsing or not responding to prior therapy. The favorable response is likely due to NGC-Cap’s ability to distribute more 5-FU to cancer cells than monotherapy capecitabine. The promising Phase 1b safety and tolerability profile plus these early efficacy signals provide validation for further development of NGC-Cap,” stated David Young, PharmD, Ph.D., President of Research and Development at Processa. “From this Phase 1b trial, we have been able to define the MTD and the RP2DR to use in our Phase 2 Optimal Dosage Regimen trial in breast cancer in the third quarter of 2024.”

Dr. Young added, “Given the need for more effective chemotherapy treatment with improved tolerability across multiple types of cancer, we believe that NGC-Cap has the potential to provide a safer, more efficacious option to treat the different cancers for which capecitabine and 5-FU are presently used.”

The NGC-Cap Phase 1b trial is evaluating ascending doses of capecitabine when administered after a single dose of PCS6422 in Stage III or IV patients with advanced, relapsed or refractory progressive GI cancer. All patients relapsed from or failed all other treatments, including prior treatment with capecitabine or 5-FU. For all doses of capecitabine in the Phase 1b NGC-Cap trial, exposure to 5-FU was greater and exposure to FBAL was lower with a better or similar side effect profile compared with monotherapy capecitabine. In addition, preliminary analysis of the efficacy data demonstrated early evidence of anti-tumor activity of capecitabine combined with PCS6422, which was assessed using RECIST 1.1 evaluations (Response Evaluation Criteria in Solid Tumors) by scans every eight weeks.

50m shelf. Company is run by morons. Short it

nice chart

No 1 on the Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc

Processa Pharmaceuticals Presents Two Abstracts at the AACR Annual Meeting 2024 Including New Data on the NGC-Cap Phase 1b Trial

PCSA under $3

https://www.secform4.com/insider-trading/1533743.htm
More insider buying

I love retarded posts like this.

LOL.. this is total garbage. Going under a dollar and then will reverse split again to eliminate current stock holders and start all over.

bullish
https://twitter.com/StocksGambino/status/1753450735889469625

OFFERING CLOSED... STILL NO MOVEMENT PRESS RELEASE OUT 1 HOUR AGO.

Form 4 insider buys just hit.

Offering now closed-8k

Gonna get interesting when/if we get the filing that the offering is done

Curling up off the lows

please post the spectacular chart, so we can all see

Chart now looks spectacular. I’m fully loaded here ready for the next pop. I know it’s gonna be 5 -6 or seven bucks.

💪👍

Nice …me too

PALI fell off a cliff too. I just grabbed a bit more PCSA here. Will continue to add now that all bad news is out of the way.

PCSA 2.52 missed that,
was too busy with PALI FRSX SOFI

yep I should have stayed away when I sold for profit

Company did everything in their power to ensure that happened. Very poorly managed.

Remember the clowns that didn’t believe me
On the pre split crash

Predictable but this should be at or close to bottom.

Sure thing. His name is Patrick Lin fyi.

Ouch that hurts

oh good to know, thanks for reaching out

Perfect…thanks

Just spoke to CFO . NOT NEW. Effective on pricing. No new offering.

yep I took it as new, why would they file effective after they already offered?

thats putting the horse b4 the carriage right?

Just not sure if it's previous offering or a new one. That makes quite a difference.

thats why I posted and was surprised you bought after

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173723139

If it's a new offering this thing is dead

MY NEW AVG UNDER $3 NOW

BUT HOPEFULLY OUT ON BOUNCE